Evidence map›Paper›PMID 33405176›Full record

ArticleHuman cell2021

Development of a cell-based pathway modulator screening system to screen the targeted cancer therapeutic candidates.

Ponmathi Panneerpandian, Kumaresan Ganesan

Abstract read
PubMed Publisher
In one paragraph

Article in Human cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ponmathi PanneerpandianUnit of Excellence in Cancer Genetics, Department of Genetics, Centre for Excellence in Genomic Sciences, School of Biological Sciences, Madurai Kamaraj University, Tamil Nadu, Madurai, India.
Kumaresan GanesanUnit of Excellence in Cancer Genetics, Department of Genetics, Centre for Excellence in Genomic Sciences, School of Biological Sciences, Madurai Kamaraj University, Tamil Nadu, Madurai, India. kumar@oncocellomics.org.

Funding

Department of Biotechnology , Ministry of Science and Technology BT/MED/30/SP11290/2015Department of Biotechnology , Ministry of Science and Technology BT/PR4500/PIB/6/676/2012
6 · The paper itself

Abstract

To overcome the issues of poor prognosis and to tackle the non-responsiveness to various chemotherapeutics; it is necessary to develop targeted cancer therapeutic agents. Also, it is being necessary to understand the molecular targets of the drug candidates and drugs in the context of cellular signaling pathways, to make progress towards the development of targeted cancer therapeutics. Towards addressing these, we have established a cell-based and pathway-focused drug screening system for the pathways such as MYC, E2F, WNT, ERK, NRF1/2, HIF1α, p53, YY1 and NFκB. These signaling pathways are highly dysregulated in many cancers, including gastric cancer. The developed firefly luciferase assay-based screening system in gastric cancer lineage is suitable for the screening of the massive panel of drugs, drug candidates, small molecule inhibitors, chemicals and alternate drug formulations. The developed stable cell lines have been demonstrated for their pathway activity reporting features using the corresponding pathway-specific modulators. A proof-of-concept medium throughput screening focusing on YY1 signaling pathway also revealed the connection between calcium channel blockers and YY1 signaling. The developed signaling pathway screening assay cells are valuable resource and will serve as the screening platform for screening the drug libraries towards the development of targeted cancer therapeutics.

Indexed as

Antineoplastic AgentsCell Line, TumorDrug Screening Assays, AntitumorE2F Transcription FactorsHigh-Throughput Screening AssaysHumansHypoxia-Inducible Factor 1, alpha SubunitMitogen-Activated Protein KinasesNeoplasmsNF-kappa BNuclear Respiratory Factor 1Proto-Oncogene Proteins c-mycSignal TransductionTumor Suppressor Protein p53YY1 Transcription FactorAntineoplastic AgentsE2F Transcription FactorsHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitMitogen-Activated Protein KinasesMYC protein, humanNF-kappa BNRF1 protein, humanNuclear Respiratory Factor 1Proto-Oncogene Proteins c-mycTumor Suppressor Protein p53YY1 protein, humanYY1 Transcription FactorFirefly luciferase assayGastric cancerHigh-throughput screening (HTS)Signaling pathways

Identifiers

PMID33405176

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.